



Corrigendum: Potential Clinical Benefits of CBD-Rich *Cannabis* Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis

Fabricio A. Pamplona^{1*}, Lorenzo Rolim da Silva² and Ana Carolina Coan³

¹ Entourage Phytolab, São Paulo, Brazil, ² Bedrocan Brasil, São Paulo, Brazil, ³ UNICAMP, Campinas, Brazil

Keywords: cannabinoids, cannabidiol (CBD), epilepsy, meta-analysis, refractory epilepsy, phytotherapy

A Corrigendum on

Potential Clinical Benefits of CBD-Rich *Cannabis* Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis

by Pamplona, F. A., da Silva, L. R., and Coan, A. C. (2018). *Front. Neurol.* 9:759. doi: 10.3389/fneur.2018.00759

In the original article, there was a mistake in **Table 2** as published. The total number of one reference was wrongly included in the calculation of the endpoint efficacy over 70%. Where it reads 83/430, it should be 83/311, therefore 27% (instead of 19%). The corrected **Table 2** appears below.

In the original article, there was a mistake in **Table 4** as published. Data from one reference was missing in the calculation of the endpoints mild AE and severe AE. Where it reads 285/663, it should be 308/663, therefore 46% (instead of 43%). Where it reads 64/487, it should be 64/483. The corrected **Table 4** appears below.

In the original article, due to the errors in **Tables 2, 4** mentioned above, corrections have been made to the **Abstract** as well as the **Results**, paragraphs one, two, three and five:

- “81/223, 36%” changed to “81/175, 46%” in Abstract and Results, paragraph one.
- “ $p = 0.56$ ” changed to “ $p = 0.52$ ” in Abstract and Results, paragraph two.
- “97/255, 38%” changed to “122/330, 37%” in Abstract and Results, paragraph two.
- “6.1 mg/kg/day” changed to “6.0 mg/kg/day” in Abstract and Results, paragraph two.
- “27.1 mg/kg/day” changed to “25.3 mg/kg/day” in Abstract and Results, paragraph two.
- “(109/285 vs. 291/346, $p < 0.0001$) and severe (23/285 vs. 77/346, $p < 0.0001$)” changed to “(158/216, 76% vs. 148/447, 33%, $p < 0.001$) and severe (41/155, 26% vs. 23/328, 7%, $p < 0.0001$)” in Abstract and Results, paragraph five.
- “17.7 mg/kg/day” changed to “15.0 mg/kg/day” in Results, paragraph two.
- “18%” changed to “27%” in Results, paragraph three.
- “83/430” changed to “83/311” in Results, paragraph three.
- “(Table 4)” changed to reference “(11)” in Results, paragraph five.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

OPEN ACCESS

Edited and reviewed by:

Richard Lowell Bell,
Indiana University, United States

*Correspondence:

Fabricio A. Pamplona
fabriciopamplona@gmail.com

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neurology

Received: 02 November 2018

Accepted: 20 November 2018

Published: 10 January 2019

Citation:

Pamplona FA, da Silva LR and Coan AC (2019) Corrigendum: Potential Clinical Benefits of CBD-Rich *Cannabis* Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. *Front. Neurol.* 9:1050. doi: 10.3389/fneur.2018.01050

Copyright © 2019 Pamplona, da Silva and Coan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

TABLE 2 | Efficacy of treatments in the reduction of convulsive seizures (heterogeneous population).

References	Patients	Reported improvement	>50%	>70%	Mean daily dose (mg/kg/day)
Total reports	670	399/622	216/553	83/311	(2–50 mg/kg)
Mean	100%	64%	39%	27%	15.0 mg/kg
CBD pure (6)	137	37%	37%	22%	22.9 mg/kg
CBD pure (7)	7	86%	71%	57%	22 mg/kg
CBD pure (8)	13	85%	70%	46%	24.6 mg/kg
CBD pure (9)	18	72%	50%	22%	37.7 mg/kg
CBD pure (10)	48	NR	42%	NR	28.2 mg/kg
CBD-rich extract (11)	19	84%	74%	42%	7.0 mg/kg
CBD-rich extract (12)	117	85%	NR	NR	4.3 mg/kg
CBD-rich extract (28)	75	57%	33%	NR	NR
CBD-rich extract (13)	74	89%	34%	18%	<10 mg/kg
CBD-rich extract (14)	43	83%	67%	42%	3.2 mg/kg
CBD-rich extract (15)	119	49%	24%	NR	NR

Endpoints: any improvement reported, improvement > 50% ("clinical responder") and >70%, and average dose reported. NR, not reported; ?, inconclusive.

TABLE 4 | Negative secondary effects of treatment with CBD-rich *Cannabis* extracts and purified CBD described as secondary endpoints in the clinical studies.

References	<i>n</i>	Mild AE	Serious AE	Total AE
Total reports	663	308/663	64/483	326/663
Mean	100%	46%	13%	49%
CBD pure (6)	137	79%	30%	128/137
CBD pure (9)	18	67%	0%	12/18
CBD pure (8)	13	77%	NR	10/13
CBD pure (10)	48	58%	NR	28/48
CBD-rich extract (11)	19	37%	0%	7/19
CBD-rich extract (12)	117	30%	0%	35/117
CBD-rich extract (28)	75	44%	13%	33/75
CBD-rich extract (13)	74	46%	18%	34/74
CBD-rich extract (14)	43	37%	0%	16/43
CBD-rich extract (15)	119	19%	NR	23/119

*Reporting adverse events in a study population does not necessarily mean that it is related to treatment. NR, not reported.